OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Bristol Myers Squibb Invests $173 Million to Expand U.S. Radiopharmaceutical Manufacturing

When EGFR-Mutant NSCLC Becomes SCLC: Can Immunotherapy Become Relevant Again?

Manish Shah: Phase 2 NEST Trial Shows Promising Neoadjuvant BOT/BAL Results in Colon Cancer

SKYSCRAPER-07: Atezolizumab ± Tiragolumab After dCRT in Unresectable ESCC

Michelle Mitchell: HPV Self-Testing Marks a Major Step Toward Eliminating Cervical Cancer

Oncology News, Insights, Stories by OncoDaily

Community Oncology Global Congress
Not To Miss

Highlights From Community Oncology Global Congress 2026, Day 1

VIRO 2026 – Global Voices in Renal Oncology
OncoDaily

VIRO 2026 – Global Voices in Renal Oncology

NEST Trial
Gastrointestinal Oncology

Phase 2 NEST Trial: Neoadjuvant BOT/BAL in Localized Colon Cancer

FDA Approves Daraxonrasib: Here is What Oncologists Have to Say

Ryan Schoenfeld: Personalized mRNA Vaccines Mark a Turning Point in Cancer Immunotherapy

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

Multiple Myeloma in 2026: Comprehensive Clinical Update

Douglas Flora: Making Mental Health Part of Cancer Care

Pavlos Msaouel: New Therapeutic Insights in Renal Medullary Carcinoma

Lacy Hubbard: 5 African Nations Unite With the Elekta Foundation to Eliminate Cervical Cancer

Voices
Rafael Vargas Alves

Rafael Vargas Alves: The Power of Biomarkers Personalized Decisions for Oncology Patients

Julie Gralow: Why Federal Cancer Research Funding Matters for Patients

Michael Sapienza: Project Cure CRC-Funded Research Featured in Nature

Barbara Jereczek-Fossa: Looking Ahead to ESTRO Meets Asia 2026

Brianne Raulston: Fuse Oncology Celebrates Five Years of Innovation in Radiation Oncology

Prisca Githuka: Where Does the Money Go in NCD Care?

Ronald Chen: Why I Will Never Give Up Patient Care

FDA Approvals
Ziihera

FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

FDA Approves OncoSil Device for Distal Cholangiocarcinoma

FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma

FDA Grants Priority Review to RYBREVANT FASPRO After Promising 42% Response in Head and Neck Cancer

FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma

FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant RCC

FDA Approved Decnupaz, the First ADC for Adults With BPDCN

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential People in Oncology 2026 – Nominations are Open!

100 Influential Cancer Survivors on Social Media: 2026 Edition

100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2025

The 100 Most Influential CEOs in Oncology in 2025 (Full List)

The 100 Most Influential People in Oncology in 2025 (Full List)

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

Celebrities and Cancer

OncoCalendar

FDA Panel Review of GRAIL’s Galleri Multi-Cancer Early Detection Test

U.S. Food and Drug Administration (FDA)

23 Sep
Multi-Cancer

Clinical Development in LATAM: Brazil Unlocked

24 Sep
Clinical Development in LATAM

The ELPIDA Foundation for Children with Cancer and Leukemia

ELPIDA Foundation for Children with Cancer and Leukemia

02 Sep
ELPIDA Foundation

The Global Health Catalyst Summit 2026

Global Health Catalyst

18 Sep
Global Health Catalyst Summit

The Inaugural ESMO Genitourinary Cancers Asia 2027

European Society For Medical Oncology (ESMO)

15 Jan
ESMO Genitourinary Cancers Asia

Immune-oncology
ctDNA and MRD in NSCLC: Emerging Clinical Applications in the Immunotherapy Era

ctDNA and MRD in NSCLC: Emerging Clinical Applications in the Immunotherapy Era

CAR T-Cell Therapy Death Rate: Treatment-Related Mortality, Causes of Death, and Risk Factors

CD20 × CD3 Bispecific Antibodies in B-Cell Lymphoma: Real-World Safety, Efficacy, and Healthcare Use in Spain

5 Must-Read Posts About CAR-T This Week

Lung Cancer Immunotherapy: Real-World Survival and Costs in France

INTerpath-001 Trial: Personalized mRNA Cancer Vaccine for Melanoma

Tumor Mutational Burden in Immunotherapy: Why TMB Is More Than a Number

Gastrointestinal-Oncology
NEST Trial

Phase 2 NEST Trial: Neoadjuvant BOT/BAL in Localized Colon Cancer

FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

SKYSCRAPER-07: Atezolizumab ± Tiragolumab After dCRT in Unresectable ESCC

TALENTOP: Liver Resection After Atezolizumab and Bevacizumab in Locally Advanced HCC

10 Must-Read Posts In GI Oncology This Week

ctDNA Identifies High Recurrence Risk After Resection of Stage I–III Biliary Tract Cancer

Comprehensive Genomic Profiling in GI Oncology: Real-World Impact and Challenges

Breast-Oncology
ELEVATE

ELEVATE: Can Elacestrant Become a New Endocrine Backbone After CDK4/6 Inhibition?

ASCO 2026 Guideline: A Risk-Adapted Framework for Early HR-Positive, HER2-Negative Breast Cancer

Artificial Intelligence Brings TILs Into the Digital Era

Oncotype DX-Guided Chemotherapy Associated With Improved Survival in HR+/HER2− Breast Cancer

Insights From I-SPY2 Trial: Dual Immune Checkpoint Blockade Shows Promise in High-Risk ERBB2-Negative Early Breast Cancer

TQB2102 and the Evolution of HER2 Antibody-Drug Conjugates: Exploring the Role of Payload Optimisation in Breast Cancer

HER2DX Predicts Pathologic Complete Response in HER2-Positive Breast Cancer After Neoadjuvant THP

Lung-Oncology
nsclc

When EGFR-Mutant NSCLC Becomes SCLC: Can Immunotherapy Become Relevant Again?

Are We Irradiating the Immune System? Thymic Dose Emerges as a Potential Risk Factor in NSCLC

Ivonescimab Plus Chemotherapy Shows Powerful Benefit After EGFR-TKI Resistance in Advanced Lung Cancer

Dato-DXd in Lung Cancer: International Experts Define New Strategies to Manage ADC Toxicities

Lung Cancer Screening in Women: 5 Breakthrough Insights Highlight New Risk Groups

MET Exon 14 Skipping NSCLC: DECIDE-MET Trial Addresses a Critical Question in First-Line Treatment Selection

KEYNOTE-671: Five-Year Data Confirm Durable Benefit of Perioperative Pembrolizumab in Early-Stage NSCLC

OncoDaily TV
WHO

Mission is possible: WHO said 2030 – Rwanda said 2027: Dr. Sabin Nsanzimana

Current Landscape

The Current Landscape & Future of CAR-T in Aggressive B-Cell Lymphoma

Experts by Experience

Experts by Experience with Carmen Monge

Fighting Cervical Cancer

From Engineering to Fighting Cervical Cancer

Dr. Beatrice Addai Wiafe

Fighting Cancer With Peace And Love: Dr. Beatrice Addai Wiafe

Maggie Smith breast cancer

Dame Maggie Smith and Courageus Breast Cancer Journey: Filming Harry Potter During Chemotherapy

Petra Jankowska

Leading with Humanity in Modern Oncology: Dr. Petra Jankowska

Princess Dina

Episode 18: Global Health Dialogues with Princess Dina and Dr Urvi Shah

Empowering Oncologist

Empowering Oncologists: How to Fight Burnout? Dr. Mimi Knoll

Dr. C.S. Pramesh

The Power of Collaboration in Fighting Cancer: Dr. C.S. Pramesh

Tommy Bramley

Making Innovative Oncology Therapies Accessible for All Patients: Tommy Bramley

Rolando Camacho

Beyond the Policy Paper: Turning Cancer Plans into Real Impact: Dr. Rolando Camacho

Not To Miss
Community Oncology Global Congress

Highlights From Community Oncology Global Congress 2026, Day 1

China NMPA Conditionally Approves HUTCHMED’s ATLED (Fanregratinib) for FGFR2-Altered Intrahepatic Cholangiocarcinoma

FDA Approves Rasonque (Daraxonrasib), First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

Agenus Reports No Recurrences and Deep Pathologic Responses With Neoadjuvant BOT+BAL in Resectable Colon Cancer

Dolly Parton Dies at 80 After Brief Battle With Cancer

Top 10 Cancer Research Grants Open to Researchers Worldwide

Astellas Doses First Patient in Phase 3 ASP2138 Trial for CLDN18.2-Positive Gastric and GEJ Cancer

OncoGrants
Science Research Education Program

NCI Youth Enjoy Science Research Education Program 2026

Nanotechnology Cancer Interventions

NCI Toward Translation of Nanotechnology Cancer Interventions R01 Grant 2026

Inflammation in Cancer R01 Grant

NCI Molecular Imaging of Inflammation in Cancer R01 Grant 2026

Bariatric Surgery R01 Grant

NCI Mechanisms That Impact Cancer Risk After Bariatric Surgery R01 Grant 2026

NCI Exploratory Grants

NCI Exploratory Grants in Cancer Control 2026

Discovery Programme Foundation

Cancer Research UK Discovery Programme Foundation Award 2026

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: The Current Landscape and Future Perspectives

CancerWorld

Oncologists
Leandro Jonata de Carvalho Oliveira

Leandro Jonata de Carvalho Oliveira

Oncologists Location São Paulo, Brazil
Shui Yen Soh

Shui Yen Soh

Oncologists Location Singapore, Singapore
Charbel Matar

Charbel Matar

Oncologists Location Washington, USA
Javier David Benítez

Javier David Benítez

Oncologists Location Elche, Spain
Zainab Shinkafi-Bagudu

Zainab Shinkafi-Bagudu

Oncologists Location Abuja, Nigeria
Gabriëlle van Ramshorst

Gabriëlle van Ramshorst

Oncologists Location Ghent, Belgium
Nagashree Seetharamu

Nagashree Seetharamu

Oncologists Location Long Island, USA
Vlad Alexandru Gâta

Vlad Alexandru Gâta

Oncologists Location Cluj-Napoca, Romania

Oncology Drugs
OTX-2002: Innovative MYC-Targeting mRNA Therapy, Dose, Administration, and Clinical Trials

OTX-2002: Innovative MYC-Targeting mRNA Therapy, Dose, Administration, and Clinical Trials

mRNA-4359: Promising Cancer Vaccine, Dose, Administration, and Clinical Trials

BXCL701: Promising Innate Immune Activation, Dose, Administration, And Clinical Trials

NBTXR3: Promising Radioenhancer, Administration, Dose, And Clinical Trials

KT-333: Promising STAT3 Degradation, Dose, Administration, And Clinical Trials

Veliparib: Mechanism, Dose, Administration, And Clinical Trials

Adavosertib: Mechanism, Dose, Administration, And Clinical Trials

OncoDaily Magazine

New Paper Alert
Jacob Scott

Jacob Scott: Bringing Rectal Cancer Radiotherapy Into the Genomic Era

Valsamo Anagnostou

Valsamo Anagnostou: New Molecular Response Marker Could Transform Immunotherapy Monitoring

Pashtoon Kasi

Pashtoon Kasi: NEST Trial Reports 100% Disease-Free Survival to Date in Localized Colon Cancer

Walid Kamoun

Walid Kamoun: The Next Challenge for RAS Inhibitors - Acquired Resistance

Felipe Couñago

Felipe Couñago: Whole-Pelvis Radiotherapy Shows No Overall Survival Benefit

Al-Ola Abdallah

Al-Ola A Abdallah: What Did We Learn From the CANOVA Phase III Trial?

OncoDaily Medical Journal

GI Oncology

10.69690/ODMJ-018-0826-7959

From Plate to Polyps: Dietary N-Nitrosamines and Biomarkers of DNA Damage
Abstracts

Head and Neck Cancer

10.69690/ODMJ-018-0826-7933

A Service Review of PD-L1 Biomarker Use in the Head and Neck Cancer Service
Abstracts

Radiation Oncology

10.69690/ODMJ-018-0826-7920

Short-Course Palliative Radiotherapy for Tumour-Related Bleeding in End-of-Life Care: A Focused Literature Review
Abstracts

Pediatric Oncology

10.69690/ODMJ-018-0826-7952

FLASH radiotherapy: A Potential Way to Protect the Developing Brain in Pediatric Oncology
Abstracts

GI Oncology

10.69690/ODMJ-018-0826-7947

Real World Clinical Insights in Combination of Trifluridine-Tipiracil with Bevacizumab for Metastatic Colorectal Cancer
Abstracts

Hematology

10.69690/ODMJ-018-0826-7945

Plasma cell survival: The impact of extracellular ATP
Abstracts

Breast Cancer

10.69690/ODMJ-018-0826-7965

A Systematic Comparison of ICG Fluorescence vs Dual-Tracer Sentinel Lymph Node Biopsy in Breast Cancer Staging
Abstracts

Immunotherapy

10.69690/ODMJ-018-0826-7715

Promoter DNA methylation regulates MHC class II transcription in human ovarian cancer
Abstracts